Dissecting the mechanisms of how MYH7 S2 mutations lead to genetic hypertrophic cardiomyopathy
剖析MYH7 S2突变导致遗传性肥厚型心肌病的机制
基本信息
- 批准号:10687810
- 负责人:
- 金额:$ 6.95万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-07-01 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:AddressAdultAffectAllelesAmino AcidsBenignBiopsyBloodCRISPR/Cas technologyCardiacCardiac MyocytesCardiac MyosinsCellular biologyClassificationClinVarClinicalDataDiagnosisDiagnosticDiseaseFamilial Hypertrophic CardiomyopathyFunctional disorderGenesGeneticGenetic TranscriptionGoalsHeartHeart failureHumanHypertrophic CardiomyopathyInterventionLaboratory ResearchLeadLeft Ventricular HypertrophyMedicineMentorshipMethodsModelingMutationMyosin ATPaseMyosin Heavy ChainsOutcomePathogenesisPathogenicityPatientsPhenotypePhotobleachingProtein DeficiencyProtein IsoformsProteinsPumpRecoveryReportingRiskRodent ModelRoleSarcomeresSeveritiesSiteTestingTherapeuticThick FilamentTissue EngineeringTrainingUniversitiesVariantWashingtonWorkcardiac tissue engineeringclinical applicationcollaborative environmentdiagnostic strategydiagnostic tooleconomic impactexperimental studyimprovedinduced pluripotent stem cellinduced pluripotent stem cell derived cardiomyocytesinherited cardiomyopathymiddle agemutantmyosin-binding protein Cnovelnovel diagnosticsnovel therapeuticsoverexpressionpredictive toolsrapid techniquerestorationsupportive environmentvariant of unknown significanceyeast two hybrid system
项目摘要
Familial hypertrophic cardiomyopathy (HCM) is a genetic cardiomyopathy affecting 1 in 500 US adults.1,2
Mutation in myosin heavy chain seven (MYH7), a sarcomeric thick filament protein, accounts for 20-40% of HCM
cases.3,4 However, current understanding lacks a generalizable mechanism through which specific MYH7
variants result in HCM, and no specific disease-modifying therapy exists.5 The MYH7 S2 domain, host to
numerous identified pathogenic variants, interacts with the C1C2 domain of cardiac myosin binding protein C
(cMyBP-C).6 We have generated hiPSC-derived cardiomyocytes (hiPSC-CMs) from an HCM patient with MYH7
variant E848G. Our preliminary data suggest E848G disrupts the S2/C1C2 interaction and reduces MYH7
abundance. Thus, my central hypothesis is pathogenic MYH7 S2 variants that disrupt S2/C1C2 interaction
and reduce MYH7 protein abundance result in contractile function; restoration of S2/C1C2 interaction
(Aim 1) or MYH7 abundance (Aim 2) may improve contractile function. My specific aims are to: (1)
demonstrate disruption of MYH7 S2/C1C2 interaction results in contractile dysfunction; and (2) elucidate the
mechanism of E848G-induced loss of MYH7 protein abundance and test whether restoring normal MYH7 protein
abundance can rescue contractile function. I will generate pathogenic MYH7 S2 variants with CRISPR/Cas9 for
use in a mammalian two-hybrid approach to quantify dysfunction of the S2/C1C2 interaction. I will restore
S2/C1C2 interaction disrupted by pathogenic MYH7 S2 variant by targeted mutation of the complementary amino
acid in C1C2, ideally recovering contractile function in corresponding engineered heart tissues (EHTs). These
findings will be applied to MYH7 S2 variants of unknown significance to test for S2/C1C2 integrity and verify in
hiPSC-CMs. This aim will establish a novel rapid method to functionally reclassify MYH7 S2 variants of unknown
significance. In the second aim, I will characterize hypocontractility in EHTs derived from MYH7-E848G hiPSC-
CMs and correlate with observed loss in MYH7 protein abundance. I will use fluorescent recovery after
photobleaching (FRAP) to capture the dynamics of MYH7 cycling in sarcomeres with and without the E848G
variant. Overexpression of MYH7 and silencing of the mutant allele will test the relationship between MYH7
abundance and contractile function. These findings will then be corroborated in other MYH7 pathogenic variants.
This aim will establish a generalizable mechanism through which MYH7 variants lose MYH7 protein abundance
and consequently lose contractile function. In sum, these experiments will enable diagnostic tools for predicting
pathogenicity of MYH7 S2 variants and therapeutic approaches to address contractile function. This project will
take place in the highly supportive and collaborative environment of the University of Washington Department of
Medicine. With the mentorship of my Sponsor and Co-Sponsor (Dr. Daniel Yang and Dr. Charles E. Murry,
respectively), this project will provide the training required for me to realize my goal of establishing an
independent research laboratory at the crossroads of cellular biology, tissue engineering, and clinical application.
家族性肥厚性心肌病 (HCM) 是一种遗传性心肌病,每 500 名美国成年人中就有 1 人患有这种疾病。1,2
肌球蛋白重链七 (MYH7)(一种肌节粗丝蛋白)的突变占 HCM 的 20-40%
3,4 然而,目前的理解缺乏一种通用的机制,通过该机制特定的 MYH7
变异会导致 HCM,并且不存在特定的疾病缓解疗法。5 MYH7 S2 结构域,宿主
许多已鉴定的致病变异,与心肌肌球蛋白结合蛋白 C 的 C1C2 结构域相互作用
(cMyBP-C).6 我们从患有 MYH7 的 HCM 患者中产生了 hiPSC 衍生的心肌细胞 (hiPSC-CM)
变体 E848G。我们的初步数据表明 E848G 破坏了 S2/C1C2 相互作用并减少了 MYH7
丰富。因此,我的中心假设是致病性 MYH7 S2 变异会破坏 S2/C1C2 相互作用
降低 MYH7 蛋白丰度导致收缩功能; S2/C1C2 相互作用的恢复
(目标 1)或 MYH7 丰度(目标 2)可能会改善收缩功能。我的具体目标是:(1)
证明 MYH7 S2/C1C2 相互作用的破坏会导致收缩功能障碍; (2) 阐明
E848G诱导MYH7蛋白丰度丧失的机制并测试是否恢复正常的MYH7蛋白
丰富可以挽救收缩功能。我将使用 CRISPR/Cas9 生成致病性 MYH7 S2 变体
在哺乳动物双杂交方法中用于量化 S2/C1C2 相互作用的功能障碍。我会恢复
通过互补氨基酸的靶向突变,致病性 MYH7 S2 变体破坏了 S2/C1C2 相互作用
C1C2 中的酸,理想地恢复相应工程心脏组织 (EHT) 的收缩功能。这些
研究结果将应用于意义不明的 MYH7 S2 变体,以测试 S2/C1C2 完整性并在
hiPSC-CM。这一目标将建立一种新颖的快速方法,对未知的 MYH7 S2 变体进行功能重新分类
意义。在第二个目标中,我将描述源自 MYH7-E848G hiPSC 的 EHT 的低收缩性。
CM 和 与观察到的 MYH7 蛋白丰度损失相关。之后我将使用荧光恢复
使用和不使用 E848G 的情况下进行光漂白 (FRAP) 以捕获肌节中 MYH7 循环的动态
变体。 MYH7的过度表达和突变等位基因的沉默将测试MYH7之间的关系
丰度和收缩功能。这些发现随后将在其他 MYH7 致病变异中得到证实。
这一目标将建立一种通用机制,通过该机制,MYH7 变体会失去 MYH7 蛋白丰度
并因此失去收缩功能。总之,这些实验将使诊断工具能够预测
MYH7 S2 变异的致病性和解决收缩功能的治疗方法。该项目将
在华盛顿大学的高度支持和协作的环境中进行
药品。在我的赞助商和共同赞助商(Daniel Yang 博士和 Charles E. Murry 博士)的指导下,
分别),这个项目将为我提供所需的培训,以实现我建立一个
位于细胞生物学、组织工程和临床应用十字路口的独立研究实验室。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Alexander Loiben其他文献
Alexander Loiben的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Alexander Loiben', 18)}}的其他基金
Dissecting the mechanisms of how MYH7 S2 mutations lead to genetic hypertrophic cardiomyopathy
剖析MYH7 S2突变导致遗传性肥厚型心肌病的机制
- 批准号:
10463127 - 财政年份:2022
- 资助金额:
$ 6.95万 - 项目类别:
相似海外基金
Co-designing a lifestyle, stop-vaping intervention for ex-smoking, adult vapers (CLOVER study)
为戒烟的成年电子烟使用者共同设计生活方式、戒烟干预措施(CLOVER 研究)
- 批准号:
MR/Z503605/1 - 财政年份:2024
- 资助金额:
$ 6.95万 - 项目类别:
Research Grant
Early Life Antecedents Predicting Adult Daily Affective Reactivity to Stress
早期生活经历预测成人对压力的日常情感反应
- 批准号:
2336167 - 财政年份:2024
- 资助金额:
$ 6.95万 - 项目类别:
Standard Grant
RAPID: Affective Mechanisms of Adjustment in Diverse Emerging Adult Student Communities Before, During, and Beyond the COVID-19 Pandemic
RAPID:COVID-19 大流行之前、期间和之后不同新兴成人学生社区的情感调整机制
- 批准号:
2402691 - 财政年份:2024
- 资助金额:
$ 6.95万 - 项目类别:
Standard Grant
Migrant Youth and the Sociolegal Construction of Child and Adult Categories
流动青年与儿童和成人类别的社会法律建构
- 批准号:
2341428 - 财政年份:2024
- 资助金额:
$ 6.95万 - 项目类别:
Standard Grant
Elucidation of Adult Newt Cells Regulating the ZRS enhancer during Limb Regeneration
阐明成体蝾螈细胞在肢体再生过程中调节 ZRS 增强子
- 批准号:
24K12150 - 财政年份:2024
- 资助金额:
$ 6.95万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Understanding how platelets mediate new neuron formation in the adult brain
了解血小板如何介导成人大脑中新神经元的形成
- 批准号:
DE240100561 - 财政年份:2024
- 资助金额:
$ 6.95万 - 项目类别:
Discovery Early Career Researcher Award
Laboratory testing and development of a new adult ankle splint
新型成人踝关节夹板的实验室测试和开发
- 批准号:
10065645 - 财政年份:2023
- 资助金额:
$ 6.95万 - 项目类别:
Collaborative R&D
Usefulness of a question prompt sheet for onco-fertility in adolescent and young adult patients under 25 years old.
问题提示表对于 25 岁以下青少年和年轻成年患者的肿瘤生育力的有用性。
- 批准号:
23K09542 - 财政年份:2023
- 资助金额:
$ 6.95万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Identification of new specific molecules associated with right ventricular dysfunction in adult patients with congenital heart disease
鉴定与成年先天性心脏病患者右心室功能障碍相关的新特异性分子
- 批准号:
23K07552 - 财政年份:2023
- 资助金额:
$ 6.95万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Issue identifications and model developments in transitional care for patients with adult congenital heart disease.
成人先天性心脏病患者过渡护理的问题识别和模型开发。
- 批准号:
23K07559 - 财政年份:2023
- 资助金额:
$ 6.95万 - 项目类别:
Grant-in-Aid for Scientific Research (C)